RAP 0.00% 20.5¢ resapp health limited

Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-39

  1. 152 Posts.
    lightbulb Created with Sketch. 21
    Hey D The 1% refers to the number of patients who could not be analysed by the App in the new FDA trial. The previous 70% from the first FDA is the total number of 'coughs' results that were effected for various reasons. If 70% of patients presenting were excluded the App would be worthless. I hope this helps.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.